Avrobio, Inc.

( )
AVRO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.37%283.400.0%$3951.53m
BNTXBioNTech SE -3.55%291.940.0%$1261.44m
NVAXNovavax, Inc. -0.60%181.7578.2%$864.57m
AMGNAmgen, Inc. 1.05%213.531.4%$651.58m
LGVNLongeveron Inc. 11.85%21.900.0%$515.31m
GILDGilead Sciences, Inc. 0.09%69.711.0%$515.13m
VRTXVertex Pharmaceuticals, Inc. 0.68%206.611.9%$454.10m
REGNRegeneron Pharmaceuticals, Inc. 2.98%654.042.7%$419.38m
ILMNIllumina, Inc. 1.77%375.983.3%$351.77m
SNSSSunesis Pharmaceuticals, Inc. 1.16%4.360.7%$304.78m
BIIBBiogen, Inc. 3.48%234.721.8%$297.97m
SGENSeagen Inc. 2.12%149.555.8%$157.99m
EXASEXACT Sciences Corp. 3.48%86.2618.0%$150.95m
INCYIncyte Corp. 0.90%67.332.4%$147.13m
BMRNBioMarin Pharmaceutical, Inc. 2.62%88.384.2%$138.75m

Company Profile

Avrobio, Inc. engages in the development of lentiviral-based gene therapies. It focuses on developing potentially curative ex vivo lentiviral-based gene therapies to treat patients with rare diseases following a single dose treatment regimen. The firm's clinical-stage programs include Fabry, Gaucher Type 1, Hunter syndrome Gaucher Type 3, Pompe, and Cystinosis. The company was founded by Geoff Mackay, Kim Warren, Christopher Mason, and Jeffrey Medin in 2015 and is headquartered in Cambridge, MA.